GFR inhibitors

Question 1

GF inhibitor drugs

Answer 1

cetuximab

panitumumab

necitumumab

erlotinib

afatinib

osimertinib

bevacizumab

ziv-afilbercept

ramurcirumab

sorafenib

sunitnib

pazopanib

Question 2

EGFR

Answer 2

overexpressed in solid tumors

Question 3

VEGFR

Answer 3

angiogenic growth factor

Question 4

Cetuximab: what it is, what kind of “isotype” it is, and its uses

Answer 4

chimeric monoclonal Ab against extracellular domain of EGFR: G1 isotype

combo w/irinotecan for metastatic colon cancer in “refractory setting” OR

monotherapy in patients irinotecan-refraectory OR

combo w/radiation against advanced head and neck cancer

Question 5

Panitumumab: what it is, how it works, what kind of isotype it is, clinical

Answer 5

fully human monoclonal antibody direct against EGFR ; G2 isotype

refractory metastatic CRC in pts treated with other agents.

combins with FOLFOX chemo regimen in front line treatment of metastatic CRC

folfox regimen: oxaliplatin + 5 FU + folinic acid (leocovorin)

Question 6

first line tx for metastatic NSCLC

Answer 6

erlotinib

Question 7

used as maintenance therapy for metastatic NSCLC whose diz has not progressed after four cycles of platinum based chemo

Answer 7

erlotinib

Question 8

diarrhea, aceniform rash, inihbits EGFR receptors

Answer 8

erlotinib

Question 9

first line tx against CML

Answer 9

imatinib

Question 10

fluid retention with periorbital edema

Answer 10

imatinib

Question 11

inhibits BCR-ABL, c-KIT and PDGFR-β tyrosine kinases

Answer 11

dasatinib

Question 12

indicated for CML as well ass 9;22+ ALL

Answer 12

dasatinib

Question 13

fully human IgG1 monoclonal antibody direct against EGFRs

Answer 13

necitumumab

Question 14

combined with gemcitabine and cisplatin chemo tx for squamous NSCLC

Answer 14

necitumumab

Question 15

first line tx for metastatic NSCLC with EGFR mutations

Answer 15

afatinib

Question 16

small molecule inhibitor of TKIs associated with EGFR, HER2, and HER4

Answer 16

afatinib

Question 17

targets metastatic NSCLC w/EGFR T790M. what makes me distinct?

Answer 17

osimertinib: unique cardiotoxicity- QTc prolongation and cardiomyopathy

Question 18

recombinant humanized monoclonal antibody that targets VEGF-A

Answer 18

bevacizumab

Question 19

cetuximab vs panitumumab: molecule, isotype, immunonological effect

Answer 19

cetuximab: chimeric monoclonal antibody against EGFR
panitumumab: fully human monoclonal antibody EGFR

cetuximab: G1 isotype
panitumumab: G2 isotype

cetuximab- immunosystem stim
panti- no immune system stim

Question 20

VEGF receptor inhibiting drugs

Answer 20

ziv-afilvercept
ramucriumab
sorafenib
sunitinib
pazopanib

Question 21

used in pts deemed refractory to irinotecan

Answer 21

cetuximab

Question 22

combined with radiation therapy in pts with locally advanced head and neck cancer

Answer 22

cetuximab

Question 23

colorectal cancer

Answer 23

cetuximab and penitumumab

Question 24

refractory metastatic colorectal cancer in pts treated with everything possible

Answer 24

panitumumab

Question 25

FOLFOX combination therapy

Answer 25

frontline chemo regimen used is metastatic CRC | oxaliplatin + 5FU+folinic acid

Question 26

approved for used with gemcitabine for tx of advanced pancreatic cancer

Answer 26

erlotinib

Question 27

combined with f 5u, irinotecan, and ocaliplatin for metastatic colorectal cancer

Answer 27

bevacizumab

Question 28

first line tx for metastatic colorectal cancer in combo with any IV fluoropyrimidine containing regimen

Answer 28

bevacizumab

Question 29

used in the FOLFIRI regimen for patients with metastatic colorectal cancer that has progressed to oxiloplatin therapy

Answer 29

ziv-aflibercept

Question 30

recombinant fusion protein made up of portions of extracellular domains of human VEGFR 1 and 2, fused to the Fc portion of the human IgG1 molecule

Answer 30

ziv-aflibercept

Question 31

Receptor VEGFR A VEGF B and PIGF

Answer 31

ziv-aflibercept